|
Washington, DC (3 May 2023) – The Society of Interventional Oncology (SIO) proudly announces Memorial Sloan Kettering Cancer Center as the next site approved and enrolling in the society’s primary clinical trial, “Ablation with Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure.” The Memorial Sloan Kettering Cancer Center site study physicians include Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE and Sotirchos Vlasios, MD.
Dr. Constantinos T. Sofocleous is the Global Principal Investigator for the study. “We are excited and pleased to share Memorial Sloan Kettering Cancer Center is now activated and has begun patient enrollment in the ACCLAIM Trial,” said Sofocleous. “We look forward to sharing other sites in the US and Europe as they are approved for enrollment to begin.”
This multimillion-dollar trial is funded collectively through grants from Boston Scientific Corporation, NeuWave Medical, Inc. (part of Ethicon, Inc.), and Varian, a Siemens Healthineers Company.
###
About the Society of Interventional Oncology (SIO)
SIO serves as the only membership-based organization dedicated to the emerging field of interventional oncology (IO), working to establish, nurture, and support IO as the fourth pillar of cancer therapy alongside medical, surgical, and radiation oncology worldwide. IO therapies, such as embolization and tumor ablation, combine the expertise of oncology and radiology and use imaging technology to diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. For more information, please visit www.sio-central.org.
About the ACCLAIM (Ablation with Confirmation of Colorectal Liver Metastases) Trial
In this multi-center, international trial, SIO proposes to establish microwave ablation (MWA) as the preferred treatment option for selected colorectal liver metastases that can be ablated with sufficient margins. The study is the first global, prospective trial to use an objective and reproducible technical outcome in its study design, which SIO believes will drive important changes to future treatment guidelines. The study will incorporate software to assess the ablation zone and margins and determine if achieving complete margins during an ablation equates to procedural success, where the primary outcome is local disease progression at two-years post-ablation. For more information, please visit, www.sio-central.org/page/acclaim.
| 
